Lode Debrabandere
Director/Board Member at Prolexys Pharmaceuticals, Inc.
Profile
Lode Debrabandere is currently a Director at Prolexys Pharmaceuticals, Inc. He previously worked as the President, Chief Executive Officer & Director at Osiris Therapeutics, Inc. from 2014 to 2016.
He was also the President, Chief Executive Officer & Director at Elutia, Inc. and a Vice President-Strategic Marketing at Bristol Myers Squibb Co. Dr. Debrabandere holds an MBA and a doctorate from Katholieke Universiteit Leuven.
Lode Debrabandere active positions
Companies | Position | Start |
---|---|---|
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Director/Board Member | - |
Former positions of Lode Debrabandere
Companies | Position | End |
---|---|---|
ELUTIA INC. | Chief Executive Officer | 2018-06-03 |
OSIRIS THERAPEUTICS, INC. | Chief Executive Officer | 2016-02-02 |
BRISTOL-MYERS SQUIBB COMPANY | Sales & Marketing | - |
Training of Lode Debrabandere
Katholieke Universiteit Leuven | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
ELUTIA INC. | Health Technology |
Private companies | 2 |
---|---|
Osiris Therapeutics, Inc.
Osiris Therapeutics, Inc. BiotechnologyHealth Technology Osiris Therapeutics, Inc. engages in the research, development, manufacture, and commercialization of regenerative medicine products. Its biosurgery business focuses on using unique tissue preservation technologies to develop viable human tissue products designed to improve wound closure and surgical outcomes for patients and physicians over standard of care alone. The company was founded by Peter A. Friedli and James S. Burns on December 23, 1992 and is headquartered in Columbia, MD. | Health Technology |
Prolexys Pharmaceuticals, Inc.
Prolexys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest. The result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include: a) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity, b) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and c) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation. | Health Technology |
- Stock Market
- Insiders
- Lode Debrabandere